

4TH ANNUAL DIABETES CONGRESS & 5th World Congress on NURSING AND HEALTHCARE

April 15-16, 2019 | Milan, Italy

Glucose toxicity: The worldwide problem and the all-natural solution

John F Burd
Lysulin, Inc., California

Glucose toxicity leads to the development of Type 2 diabetes in both children and adults, costing our healthcare systems a huge amount to treat diabetes and its complications. Chronic hyperglycemia leads to insulin resistance. Insulin resistance can lead to insulin depletion. When this happens, we may have to resort to injection of insulin in order to try to keep our blood glucose levels in the normal range. Glucose is not a passive bystander in our bloodstream but is a toxic and reactive compound. Glucose reacts with all of the proteins in our body forming glycated proteins. These glycated proteins progress to become what is known as advanced glycation endproducts or ages. These AGEs are known to be the culprits in many disease complications including cardiovascular disease. Protein glycation is

also being the cause of insulin resistance. If insulin and the insulin receptors on cells become glycated, this changes their ability to effectively function. There is now an all-natural solution to the glucose toxicity problem. In over 20 years of R&D and clinical studies, nutritional supplements have been proven to combat glucose toxicity. Three important supplements having this ability are the lysine, zinc and vitamin C. Combining these three important supplements into one tablet makes a powerful weapon to combat glucose toxicity and protein glycation. This weapon is Lysulin[®]. Current therapy for type 2 diabetes and the history of studies proving the effectiveness of nutritional supplements will be presented along with recent data from double blind placebo controlled studies with Lysulin.

Biography

John F Burd is the founder & CEO of Lysulin Inc, developing scientifically proven nutraceutical products to improve the health of people with diabetes. He is also the co-founder of Sabur Technology Inc., developing a new non-invasive continuous glucose monitoring technology. He is the former president and CEO of DexCom, where he directed the company's work to develop, manufacture and market the first long-term implantable glucose sensor for people with diabetes.

jburd@jburd.com

Notes: